Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy that blocks both histamine-1 (H1) and histamine-2 (H2) receptors. Cetirizine is an antihistamine that primarily affects the respiratory system and skin by blocking H1 receptors, while famotidine blocks gastric H2 receptors to decrease stomach acid production. This dual-histamine receptor blockade has been studied for various conditions including COVID-19, interstitial cystitis/bladder pain syndrome, and allergic conditions. The combination has shown beneficial effects in reducing inflammation and cytokine release.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetirizine + famotidine.